u/Duke_Rubio

Author argues Thor Medical is a Norwegian thorium isotope supplier whose AlphaOne plant is complete and in commercial production, with first deliveries done, self-scaling output, and a cited ~NOK 850m backlog from named radiopharma customers. The author sees revenue potential around NOK 330–350m at 21k patient-dose equivalents and positive EBITDA targeted around 2027, with a NOK 300m raise funding a US expansion called AlphaGlobal. The stock is viewed as cheap because plant risk is largely behind, cash is in, and the market gives little credit to a ~NOK 677m tax-loss carryforward from the old Nordic Nanovector shell. Main stated risks include dilution, a disclosed Two Sigma short, an ongoing subsequent offering, and the fact that drug or device approvals do not guarantee Thor wins every isotope kilo.